Neonatal Respiratory Distress Syndrome Treatment Market Set for Strong Growth as Preterm Births and Advanced Neonatal Care Drive DemandNeonatal Respiratory Distress Syndrome Treatment Market Overview
The Neonatal Respiratory Distress Syndrome Treatment Market is expanding as healthcare systems increase their focus on premature infants, neonatal intensive care, and advanced respiratory-support technologies. According to Maximize Market Research, the market was valued at USD 778.2 million in 2022 and is expected to grow at a CAGR of 7.5% from 2023 to 2029, reaching nearly USD 1,291.07 million by 2029. Neonatal respiratory distress syndrome (NRDS) primarily affects premature newborns whose lungs have not developed sufficiently and who may have inadequate pulmonary surfactant. The market includes surfactant replacement therapy, oxygen therapy, mechanical ventilation, and other supportive interventions. Rising preterm births remain a key growth driver, while improvements in neonatal intensive care units (NICUs), early diagnosis, non-invasive ventilation, and surfactant therapies are creating additional opportunities. The report highlights minimally invasive surfactant administration (MIST), non-invasive ventilation, personalized medicine, and genetic testing as promising areas for future development. High treatment costs and limited access to specialized neonatal facilities in low-resource regions remain important challenges.
* Get Actionable Market Insights: https://www.maximizemarketresearch.com/request-sample/211019/
US Market Trends and Investment
The United States remains a major market because of its established NICU infrastructure, advanced neonatal technologies, specialized clinicians, and significant public research funding. CDC data published in March 2025 showed that the percentage of US infants admitted to NICUs increased from 8.7% in 2016 to 9.8% in 2023, while NICU admission among preterm infants increased from 49.1% to 51.6% over the same period. US public investment is also supporting research into neonatal respiratory conditions. In fiscal 2025, NIH awarded $343,189 to a project focused on neonatal respiratory distress and preterm infant health, while another NIH-supported project received $1.91 million for research involving neonatal respiratory distress, pulmonary hypertension, genetics, and personalized interventions. The FDA also highlighted the importance of maintaining supplies of neonatal breathing tubes and ventilators in January 2025, emphasizing the particular vulnerability of premature infants to medical-device shortages.
Market Segmentation
According to Maximize Market Research, the market is segmented by Therapy, End User, and Region. By therapy, Surfactant Therapy holds a significant market share because surfactant replacement is an established treatment for premature infants with insufficient surfactant production. Administering exogenous surfactant improves lung function and helps reduce complications associated with NRDS. Mechanical ventilation is also widely used in severe cases, while oxygen therapy and other supportive interventions remain important components of neonatal respiratory care.
By end user, the market includes Hospitals, Sub-acute Facilities, Home Care, Retail Pharmacies, and Other settings. Hospitals and hospital pharmacies are particularly important because NRDS treatment generally requires specialized neonatal equipment, trained clinical teams, respiratory monitoring, and access to surfactant medicines and ventilation systems.
Neonatal respiratory distress syndrome treatment Market, Key Players are
1. AbbVie Inc. (United States)
2. Chiesi Farmaceutici S.p.A. (Italy)
3. Merck & Co., Inc. (United States)
4. ONY, Inc. (United States)
5. Novartis AG (Switzerland)
6. Pfizer Inc. (United States)
7. Drägerwerk AG & Co. KGaA (Germany)
8. Fisher & Paykel Healthcare Limited (New Zealand)
9. Hamilton Medical AG (Switzerland)
10. Getinge AB (Sweden)
11. Medtronic plc (Ireland)
12. Philips Healthcare (Netherlands)
13. Masimo Corporation (United States)
14. Vyaire Medical Inc. (United States)
15. GE Healthcare (United States)
16. Smiths Medical (United Kingdom)
17. Teleflex Incorporated (United States)
18. Becton, Dickinson, and Company (United States)
19. Hill-Rom Holdings, Inc. (United States)
20. ResMed Inc. (United States)
* Get Actionable Market Insights: https://www.maximizemarketresearch.com/request-sample/211019/
Competitive Analysis
The MMR report identifies AbbVie Inc., Chiesi Farmaceutici S.p.A., Merck & Co., Inc., ONY, Inc., Novartis AG, Pfizer Inc., Drägerwerk AG & Co. KGaA, Fisher & Paykel Healthcare Limited, Hamilton Medical AG, Getinge AB, Medtronic plc, Philips Healthcare, Masimo Corporation, Vyaire Medical Inc., GE Healthcare, Smiths Medical, Teleflex Incorporated, Becton, Dickinson and Company, Hill-Rom Holdings, Inc., and ResMed Inc. as key companies. The supplied report does not disclose individual company market-share percentages, so a precise ranking of the five largest companies by global share would require unsupported assumptions.
AbbVie Inc. is one of the pharmaceutical companies identified in the report. In August 2025, AbbVie announced a $195 million investment to expand active pharmaceutical ingredient manufacturing in North Chicago, Illinois, with the facility expected to be operational in 2027. While the investment is not specifically identified as an NRDS project, strengthening domestic pharmaceutical manufacturing can support broader healthcare supply-chain resilience.
Chiesi Farmaceutici is particularly relevant to respiratory and neonatology. The company states that neonatal respiratory distress syndrome is among the areas of unmet medical need in which it seeks academic collaborations. In July 2025, Chiesi entered a strategic collaboration with Serna Bio to discover and develop RNA-targeted small molecules for respiratory diseases, demonstrating its continuing investment in innovative respiratory research.
Merck & Co. and Pfizer Inc. are among the pharmaceutical companies identified by MMR, while Drägerwerk and Fisher & Paykel Healthcare represent important medical-device and respiratory-support capabilities. Their presence reflects the market's two complementary innovation areas: pharmaceutical therapies such as surfactants and advanced respiratory-support systems such as non-invasive ventilation and neonatal ventilators.
Across the competitive landscape, innovation is increasingly centered on minimally invasive surfactant delivery, non-invasive ventilation, improved monitoring, smaller neonatal devices, and therapies capable of reducing the need for invasive mechanical ventilation.
Regional Analysis
North America dominated the Global Neonatal Respiratory Distress Syndrome Treatment Market, according to Maximize Market Research. The region benefits from well-established healthcare infrastructure, advanced neonatal-care technologies, higher awareness, specialized NICUs, government research support, and the presence of major pharmaceutical and medical-device companies.
The United States is the principal contributor to this regional position. Rising NICU admissions, increasing investment in neonatal research, and continued development of specialized respiratory equipment are supporting market demand.
Among the other specified countries, Germany, France, and the UK benefit from established healthcare systems, advanced NICU capabilities, and government support for neonatal care. Japan offers opportunities through sophisticated healthcare infrastructure and advanced neonatal technologies, while China represents a significant long-term opportunity because of its large birth population and ongoing healthcare-infrastructure development. MMR highlights Asia Pacific as a rapidly growing market because of high birth rates and increasing premature births, although access to specialized neonatal treatment remains uneven.
The supplied MMR report does not provide individual country-level market-share percentages for the specified countries, so specific country shares are not stated.
Conclusion
The Global Neonatal Respiratory Distress Syndrome Treatment Market is positioned for sustained growth as premature-birth management, NICU infrastructure, respiratory technologies, and neonatal pharmaceutical treatments continue to advance. In our view, minimally invasive surfactant administration, non-invasive ventilation, advanced neonatal monitoring, and personalized treatment strategies represent the strongest opportunities for market development.
The expansion of NICU capacity in emerging economies could significantly increase access to treatment, while technological advances can reduce dependence on invasive ventilation and improve outcomes for vulnerable newborns. At the same time, investment in reliable medical-device supply chains and specialized neonatal research will remain essential. As healthcare providers increasingly prioritize early diagnosis, less-invasive interventions, and individualized neonatal care, innovation across both pharmaceutical and respiratory-device technologies is expected to remain the major catalyst for market growth through 2029.
About Maximize Market Research
Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.
Contact Maximize Market Research
MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
? +91 9607365656
? [email protected]
Comments